Results 241 to 250 of about 66,449 (275)

Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells

Anti-Cancer Drugs, 2020
Quercetin, an abundant flavonoid found in various fruits and vegetables, displays multiple biological activities, including anticancer effects. Therefore, quercetin is receiving increasing attention as a potential adjuvant anticancer treatment. Gemcitabine (GEM) resistance is a major issue for clinicians and patients with advanced cancers, making it ...
Zhi-Jie, Liu, Wei, Xu, Jing, Han, Qing-Yan, Liu, Li-Feng, Gao, Xiao-Hui, Wang, Xiu-Li, Li   +6 more
openaire   +2 more sources

Combination of hydroxyurea and tranilast suppresses gemcitabine resistance induced by ribonucleotide reductase M1 in gemcitabine‐resistant cells

Oral Science International, 2020
AbstractIntroductionGemcitabine (GEM; 2′,2′‐difluorodeoxycytidine) is widely used to treat pancreatic, biliary tract, non‐small cell lung, bladder, mammary, and ovarian cancers. Chemoradiotherapy with GEM is a promising treatment for patients with advanced and locally recurrent head and neck cancers, including those with oral cavity cancer.
Noriho Shinagawa, Kentaro Minami, Takayuki Ishida, Hiroshi Hijioka, Masatatsu Yamamoto, Kohichi Kawahara, Tatsuhiko Furukawa, Norifumi Nakamura   +7 more
openaire   +1 more source

S100A14 promotes progression and gemcitabine resistance in pancreatic cancer

Pancreatology, 2021
S100 calcium binding protein A14 (S100A14) plays an important role in the progression of several types of cancer. However, its roles in pancreatic ductal adenocarcinoma (PDAC) are largely unexplored. Here, we characterized the functional roles of S100A14 in the progression and chemoresistance of PDAC.
Hongwei, Zhu, Wenzhe, Gao, Xia, Li, Li, Yu, Dong, Luo, Yunfei, Liu, Xiao, Yu   +6 more
openaire   +2 more sources

Mass Spectrometry-Based Metabolic Profiling of Gemcitabine-Sensitive and Gemcitabine-Resistant Pancreatic Cancer Cells

Pancreas, 2014
Gemcitabine resistance (GR) is one of the critical issues for therapy for pancreatic cancer, but the mechanism still remains unclear. Our aim was to increase the understanding of GR by metabolic profiling approach.To establish GR cells, 2 human pancreatic cancer cell lines, SUIT-2 and CAPAN-1, were exposed to increasing concentration of gemcitabine ...
Yoshinori, Fujimura, Naoki, Ikenaga, Kenoki, Ohuchida, Daiki, Setoyama, Miho, Irie, Daisuke, Miura, Hiroyuki, Wariishi, Masaharu, Murata, Kazuhiro, Mizumoto, Makoto, Hashizume, Masao, Tanaka   +10 more
openaire   +2 more sources

Abstract PR023: Targeting gemcitabine resistance in pancreatic cancer

Cancer Research, 2022
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a devastating 5-year survival rate of 11%. A lack of durable responses to standard-of-care chemotherapy combinations renders its treatment particularly challenging and largely contributes to the devastating prognosis.
Alica Katrin Beutel, Rima Singh, Cecily Anaraki, Gregory Tong, Thomas Martinez, Alexander Kleger, Zeljka Jutric, Christopher James Halbrook   +7 more
openaire   +1 more source

Abstract 3122: Combination effect of metformin with gemcitabine for gemcitabine-resistant pancreatic adenocarcinoma

Cancer Research, 2014
Abstract Metformin (MET) is the first-line treatment for type-2 diabetes mellitus. Several epidemiological studies have revealed the anti-cancer effects of metformin, including against pancreatic ductal carcinoma (PDC). Gemcitabine (GEM) has become the standard chemotherapy for PDC but tolerance to GEM is an important issue.
Keiichi Suzuki, Osamu Takeuchi, Masayoshi Osaku, Yoshinori Yamada   +3 more
openaire   +1 more source

Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones

Anti-Cancer Drugs, 2015
The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift to second agents, which are associated with the risk of cross-resistance. However, whether cross-
Hiroshi, Yoneyama, Asako, Takizawa-Hashimoto, Osamu, Takeuchi, Yukiko, Watanabe, Koichiro, Atsuda, Fumiki, Asanuma, Yoshinori, Yamada, Yukio, Suzuki   +7 more
openaire   +2 more sources

Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma

International Journal of Gynecological Cancer, 2005
Platinum compounds are the key components of chemotherapy for ovarian cancer. Preclinical models in an ovarian cancer cell line (A2780) have demonstrated synergistic activity when gemcitabine is added to cisplatin compared with either single agent alone.
openaire   +2 more sources

Gemcitabine in cisplatin-resistant ovarian cancer.

Seminars in oncology, 1996
Many new drugs have been tested in phase II studies in recent years. With a number of drugs the results vary because of differences in the patients recruited to these studies. A number of factors impact the response to second-line therapy, including the treatment-free interval between the end of previous therapy and the entry into phase II study, the ...
B, Lund, J P, Neijt
openaire   +1 more source

Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells

Annals of Surgical Oncology, 2007
Pancreatic cancer is an exceptionally lethal disease with an annual mortality nearly equivalent to its annual incidence. This dismal rate of survival is due to several factors including late presentation with locally advanced, unresectable tumors, early metastatic disease, and rapidly arising chemoresistance.
Ami N, Shah, Justin M, Summy, Jing, Zhang, Serk In, Park, Nila U, Parikh, Gary E, Gallick   +5 more
openaire   +2 more sources